The RET proto-oncogene: A molecular therapeutic target in thyroid cancer

Keyphrases

• Thyroid Cancer 100%
• Multiple Endocrine Neoplasia Type 2 (MEN2) 100%
• RET Proto-oncogene 100%
• Molecular Therapeutic Targets 100%
• Point mutation 50%
• RNA Interference 50%
• Therapeutic Approaches 50%
• Dominant Negative 50%
• Papillary Thyroid Carcinoma 50%
• Signaling Molecules 50%
• Cancer Therapeutics 50%
• Gene Therapy 50%
• Tyrosine Kinase Inhibitor 50%
• Familial Medullary Thyroid Carcinoma 50%
• Radiation-associated 50%
• Inherited Disease 50%
• RET Tyrosine Kinase 50%
• Oncogenic mutant 50%
• RET-PTC 50%
• Oncogenic Activation 50%
• Germline 50%
• Inhibitor Genes 50%

Medicine and Dentistry

• Carcinogenesis 100%
• Thyroid Cancer 100%
• Proto Oncogene 100%
• Therapeutic Target 100%
• Point Mutation 50%
• Cancer 50%
• Malignant Neoplasm 50%
• Signaling Molecule 50%
• Protein Tyrosine Kinase 50%
• Papillary Thyroid Cancer 50%
• Multiple Endocrine Neoplasia Type 2a 50%
• Thyroid Medullary Carcinoma 50%
• Gene Therapy 50%
• Genetic Disorder 50%
• Tyrosine-Kinase Inhibitor 50%
• Multiple Endocrine Neoplasia Type 2b 50%
• Induced Mutation 50%
• Germ Cell 50%
• RNAI 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Carcinogenesis 100%
• Thyroid Cancer 100%
• Malignant Neoplasm 50%
• Protein Tyrosine Kinase 50%
• Protein Tyrosine Kinase Inhibitor 50%
• Genetic Disorder 50%
• Multiple Endocrine Neoplasia Type 2a 50%
• Thyroid Medullary Carcinoma 50%
• Thyroid Papillary Carcinoma 50%
• Multiple Endocrine Neoplasia Type 2b 50%